Healthcare provider profile · identity verified

Kenneth Douglas Lecroy, M.D.

Family Practice · COLLEYVILLE, TX · NPI 1598848830

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	327	123
Levothyroxine Sodium	Levothyroxine Sodium	241	80
Atorvastatin Calcium	Atorvastatin Calcium	192	68
Amlodipine Besylate	Amlodipine Besylate	187	70
Alprazolam	Alprazolam	160	49
Metoprolol Succinate	Metoprolol Succinate	136	46
Pantoprazole Sodium	Pantoprazole Sodium	135	47
Tamsulosin Hcl	Tamsulosin Hcl	108	35
Metformin Hcl Er	Metformin Hcl	102	32
Lisinopril	Lisinopril	98	37
Gabapentin	Gabapentin	95	36
Omeprazole	Omeprazole	95	34
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	94	36
Trazodone Hcl	Trazodone Hcl	94	28
Losartan Potassium	Losartan Potassium	91	32
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	85	26
Albuterol Sulfate Hfa	Albuterol Sulfate	82	31
Furosemide	Furosemide	80	28
Metformin Hcl	Metformin Hcl	80	28
Prednisone	Prednisone	66	45
Meloxicam	Meloxicam	62	27
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	62	27
Tramadol Hcl	Tramadol Hcl	62	30
Finasteride	Finasteride	60	18
Doxazosin Mesylate	Doxazosin Mesylate	57	19
Duloxetine Hcl	Duloxetine Hcl	56	17
Ezetimibe	Ezetimibe	55	21
Simvastatin	Simvastatin	54	23
Sertraline Hcl	Sertraline Hcl	53	20
Zolpidem Tartrate	Zolpidem Tartrate	53	18
Clopidogrel	Clopidogrel Bisulfate	50	16
Farxiga	Dapagliflozin Propanediol	50	14
Quetiapine Fumarate	Quetiapine Fumarate	49	16
Temazepam	Temazepam	46	14
Fluoxetine Hcl	Fluoxetine Hcl	45	15
Olmesartan Medoxomil	Olmesartan Medoxomil	42	18
Montelukast Sodium	Montelukast Sodium	41	15
Famotidine	Famotidine	40	12
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	40	17
Allopurinol	Allopurinol	39	15
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	38	suppressed
Anastrozole	Anastrozole	37	16
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	37	18
Bupropion Xl	Bupropion Hcl	36	14
Hydrochlorothiazide	Hydrochlorothiazide	36	15
Diazepam	Diazepam	35	suppressed
Mounjaro	Tirzepatide	35	suppressed
Clonidine Hcl	Clonidine Hcl	34	19
Estradiol	Estradiol	34	11
Ozempic	Semaglutide	34	11
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	34	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	33	25
Liothyronine Sodium	Liothyronine Sodium	31	suppressed
Azithromycin	Azithromycin	29	27
Carvedilol	Carvedilol	29	12
Escitalopram Oxalate	Escitalopram Oxalate	29	11
Esomeprazole Magnesium	Esomeprazole Magnesium	29	11
Methylprednisolone	Methylprednisolone	29	27
Fluticasone Propionate	Fluticasone Propionate	27	11
Solifenacin Succinate	Solifenacin Succinate	27	suppressed
Donepezil Hcl	Donepezil Hcl	26	suppressed
Pregabalin	Pregabalin	26	suppressed
Primidone	Primidone	26	suppressed
Amoxicillin	Amoxicillin	25	17
Atenolol	Atenolol	25	12
Citalopram Hbr	Citalopram Hydrobromide	25	suppressed
Nifedipine Er	Nifedipine	25	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	24	suppressed
Eliquis	Apixaban	23	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	23	11
Mirtazapine	Mirtazapine	23	suppressed
Pravastatin Sodium	Pravastatin Sodium	23	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Promethazine Hcl	Promethazine Hcl	22	suppressed
Testosterone Cypionate	Testosterone Cypionate	22	suppressed
Alendronate Sodium	Alendronate Sodium	21	suppressed
Buspirone Hcl	Buspirone Hcl	21	suppressed
Clonazepam	Clonazepam	21	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	21	14
Ondansetron Hcl	Ondansetron Hcl	21	suppressed
Potassium Chloride	Potassium Chloride	21	13
Clonidine	Clonidine	20	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	19	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	19	suppressed
Spironolactone	Spironolactone	19	suppressed
Synthroid	Levothyroxine Sodium	19	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	19	suppressed
Clarithromycin	Clarithromycin	18	18
Lubiprostone	Lubiprostone	18	suppressed
Methocarbamol	Methocarbamol	18	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	18	suppressed
Xarelto	Rivaroxaban	18	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	17	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	17	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	16	suppressed
Symbicort	Budesonide/Formoterol Fumarate	16	suppressed
Glimepiride	Glimepiride	15	suppressed
Lorazepam	Lorazepam	15	suppressed
Rizatriptan	Rizatriptan Benzoate	15	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	15	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	14	suppressed
Valacyclovir	Valacyclovir Hcl	14	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	13	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	13	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Meclizine Hcl	Meclizine Hcl	13	suppressed
Propranolol Hcl Er	Propranolol Hcl	13	suppressed
Zubsolv	Buprenorphine Hcl/Naloxone Hcl	13	suppressed
Armodafinil	Armodafinil	12	suppressed
Celecoxib	Celecoxib	12	suppressed
Lamotrigine	Lamotrigine	12	suppressed
Metronidazole	Metronidazole	12	suppressed
Rytary	Carbidopa/Levodopa	12	suppressed
Tizanidine Hcl	Tizanidine Hcl	12	suppressed
Trulicity	Dulaglutide	12	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	11	suppressed
Hydralazine Hcl	Hydralazine Hcl	11	suppressed
Naproxen	Naproxen	11	suppressed
Telmisartan	Telmisartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error